INTRODUCTION: Nonpharmacological treatment of patients with hypertrophic obstructive cardiomyopathy (HOCM) comprises surgical myectomy (SME), alcohol septal ablation (ASA), and dual-chamber (DDD) pacing. The aim of the study was to compare the long-term effect of DDD pacing and ASA in symptomatic HOCM patients. PATIENTS AND METHODS: We evaluated retrospective data from three cardiocenters; there were 24 patients treated with DDD pacing included and 52 treated with ASA followed for 101 ± 49 and 87 ± 23 months, respectively. RESULTS: In the group treated with DDD pacing, the left ventricle outflow tract gradient (LVOTG) decreased from 82 ± 44 mmHg to 21 ± 21 mmHg, and NYHA class improved from 2.7 ± 0.5 to 2.1 ± 0.6 (both P < 0.001). In the ASA-treated group, a decline in LVOTG from 73 ± 38 mmHg to 24 ± 26 mmHg and reduction in NYHA class from 2.8 ± 0.5 to 1.7 ± 0.8 were observed (both P < 0.001). The LVOTG change was similar in both groups (P = 0.264), and symptoms were more affected by ASA (P = 0.001). CONCLUSION: ASA and DDD pacing were similarly effective in reducing LVOTG. The symptoms improvement was more expressed in patients treated with ASA.

Department of Cardiovascular Diseases St Anne's University Hospital International Clinical Research Center and Masaryk University Pekařská 53 656 91 Brno Czech Republic

See more in PubMed

Maron BJ. Hypertrophic cardiomyopathy: a systematic review. Journal of the American Medical Association. 2002;287(10):1308–1320. PubMed

Brock R. Functional obstruction of the left ventricle; acquired aortic subvalvar. Guy’s Hospital Reports. 1957;106(4):221–238. PubMed

Teare D. Asymmetrical hypertrophy of the heart in young adults. British Heart Journal. 1958;20(1):1–8. PubMed PMC

Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2009;54(3):201–211. PubMed

Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2011;124(24):e783–e831. PubMed

Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. New England Journal of Medicine. 2003;348(4):295–303. PubMed

Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation. 1998;97(5):461–466. PubMed

Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. From idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2009;54(3):191–200. PubMed

Cleland WP. The surgical management of obstructive cardiomyopathy. The Journal of Cardiovascular Surgery. 1963;4:489–491. PubMed

Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Annals of Surgery. 1961;154:181–189. PubMed PMC

Hassenstein P, Storch HH, Schmitz W. Results of electrical pacing in patients with hypertrophic obstruction cardiomyopathy. Thoraxchirurgie, vaskulare Chirurgie. 1975;23(5):496–498. PubMed

Fananapazir L, Cannon RO, III, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and β- adrenergic blocker therapy. Circulation. 1992;85(6):2149–2161. PubMed

Jeanrenaud X, Goy J-J, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. The Lancet. 1992;339(8805):1318–1323. PubMed

Slade AKB, Sadoul N, Shapiro L, et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart. 1996;75(1):44–49. PubMed PMC

Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. Journal of the American College of Cardiology. 1997;29(2):435–441. PubMed

Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. European Heart Journal. 1997;18(8):1249–1256. PubMed

Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug- refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, crossover study (M-PATHY) Circulation. 1999;99(22):2927–2933. PubMed

Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. The Lancet. 1995;346(8969):211–214. PubMed

Agarwal S, Tuzcu EM, Desai MY, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2010;55(8):823–834. PubMed

Parakh N, Bhargava B. Golden jubilee of hypertrophic cardiomyopathy: is alcohol septal ablation the gold standard? Cardiovascular Revascularization Medicine. 2009;10(3):172–178. PubMed

Megevand A, Ingles J, Richmond DR, Semsarian C. Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dual-chamber pacing. American Journal of Cardiology. 2005;95(8):991–993. PubMed

Topilski I, Sherez J, Keren G, Copperman I. Long-Term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. American Journal of Cardiology. 2006;97(12):1769–1775. PubMed

Galve E, Sambola A, Saldaña G, et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart. 2010;96(5):352–356. PubMed

Sandín M, Marín F, Cambronero F, et al. Does pacemaker implantation provide long-term benefits in severe obstructive hypertrophic cardiomyopathy? Revista Espanola de Cardiologia. 2009;62(11):1233–1239. PubMed

Mohiddin SA, Page SP. Long-term benefits of pacing in obstructive hypertrophic cardiomyopathy. Heart. 2010;96(5):328–330. PubMed

Maron BJ, McKenna WJ, Danielson GK, et al. American College of cardiology/european society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American college of cardiology foundation task force on clinical expert consensus documents and the European society of cardiology committee for practice guidelines. Journal of the American College of Cardiology. 2003;42(9):1687–1713. PubMed

Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. Journal of the American College of Cardiology. 1999;34(1):191–196. PubMed

Krejčí J, Groch L, Meluzín J, Vykypěl T, Halámek J, Vítovec J. Non-pharmacologic therapy of hypertrophic obstructive cardiomyopathy—results of therapy based on percutaneous transluminal septal myocardial ablation compared with results of dual-chamber cardiac pacing. Vnitrni Lekarstvi. 2006;52(4):313–320. PubMed

Gao Y-C, Li Y, Han Z-H, Zhang X-L, Zhao H, Jiang T-Y. Transcoronary ablation of septal hypertrophy versus dual-chamber cardiac pacing for the treatment of aged patients with hypertrophic obstructive cardiomyopathy. Zhonghua xin xue guan bing za zhi. 2007;35(4):333–336. PubMed

Qintar M, Morad A, Alhawasli H, et al. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. Cochrane Database of Systematic Reviews. 2012;(5)CD008523 PubMed PMC

Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. Journal of Interventional Cardiology. 2006;19(4):319–327. PubMed

Veselka J, Duchoňová R, Procházková Š, Páleníčková J, Sorajja P, Tesař D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. American Journal of Cardiology. 2005;95(5):675–678. PubMed

Veselka J, Zemánek D, Tomašov P, Duchoňová R, Linhartová K. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart and Vessels. 2009;24(1):27–31. PubMed

Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118(2):131–139. PubMed

McKenna WJ, Kaski JP. Pacemaker therapy in hypertrophic obstructive cardiomyopathy: stil awaiting the evidence. Revista Española de Cardiología. 2009;62:1217–1220. PubMed

Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994;90(6):2731–2742. PubMed

Gadler F, Linde C, Daubert C, et al. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. European Heart Journal. 1999;20(14):1044–1050. PubMed

Linde C, Gadler F, Kappenberger L, Rydén L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. American Journal of Cardiology. 1999;83(6):903–907. PubMed

Gadler F, Linde C, Rydén L. Rapid return of left ventricular outflow tract obstruction and symptoms following cessation of long-term atrioventricular synchronous pacing for obstructive hypertrophic cardiomyopathy. American Journal of Cardiology. 1999;83(4):553–557. PubMed

Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103(11):1492–1496. PubMed

Fang F, Zhang Q, Chan JYS, et al. Deleterious effect of right ventricular apical pacing on left ventricular diastolic function and the impact of pre-existing diastolic disease. European Heart Journal. 2011;32(15):1891–1899. PubMed

Chan JY-S, Fang F, Zhang Q, et al. Biventricular pacing is superior to right ventricular pacing in bradycardia patients with preserved systolic function: 2-year results of the PACE trial. European Heart Journal. 2011;32(20):2533–2540. PubMed

Sweeney MO, Hellkamp AS. Heart failure during cardiac pacing. Circulation. 2006;113(17):2082–2088. PubMed